cancer treatment | rituximab | Nitrosourea | Mitomycin-c | Toxicity Associated with Operative Surgical Procedures | Toxicity Associated with Therapeutic radiology procedure | Toxicity Associated with Chemotherapy | Toxicity Associated with Immunotherapy | Patient recovered
Item
1. no anti-cancer therapy for three weeks (six weeks if rituximab, nitrosourea or mitomycin c) prior to study initiation, and fully recovered from acute toxicities associated with prior surgery, radiation treatments, chemotherapy, or immunotherapy.
boolean
C0920425 (UMLS CUI [1])
C0393022 (UMLS CUI [2])
C0028210 (UMLS CUI [3])
C0002475 (UMLS CUI [4])
C0600688 (UMLS CUI [5,1])
C0332281 (UMLS CUI [5,2])
C0543467 (UMLS CUI [5,3])
C0600688 (UMLS CUI [6,1])
C0332281 (UMLS CUI [6,2])
C1522449 (UMLS CUI [6,3])
C0600688 (UMLS CUI [7,1])
C0332281 (UMLS CUI [7,2])
C0392920 (UMLS CUI [7,3])
C0600688 (UMLS CUI [8,1])
C0332281 (UMLS CUI [8,2])
C0021083 (UMLS CUI [8,3])
C1115804 (UMLS CUI [9])
Patients Treated | Indolent lymphoma refractory | Indolent lymphoma Relapse | Extranodal marginal zone B-cell lymphoma (MALT type) | Monocytoid B-cell lymphoma | Splenic Marginal Zone B-Cell Lymphoma | Splenic Marginal Zone B-Cell Lymphoma Villous Lymphocytes Not Present
Item
2. previously treated patients with a histology of refractory/relapsed indolent lymphomas including: (a) extranodal marginal lymphoma of malt type; (b) nodal marginal zone b-cell lymphoma (+/- monocytoid cells); (c) splenic marginal b-cell lymphoma (+/- villous lymphocytes).
boolean
C0030705 (UMLS CUI [1,1])
C1522326 (UMLS CUI [1,2])
C1334170 (UMLS CUI [2,1])
C0205269 (UMLS CUI [2,2])
C1334170 (UMLS CUI [3,1])
C0277556 (UMLS CUI [3,2])
C0852624 (UMLS CUI [4])
C0855139 (UMLS CUI [5])
C0349632 (UMLS CUI [6])
C0349632 (UMLS CUI [7,1])
C1519987 (UMLS CUI [7,2])
Informed Consent
Item
3. signed informed consent
boolean
C0021430 (UMLS CUI [1])
Age
Item
4. age >/= 18 years
boolean
C0001779 (UMLS CUI [1])
Life Expectancy
Item
5. expected survival >/= 3 months
boolean
C0023671 (UMLS CUI [1])
Zubrod Performance Status
Item
6. pre-study zubrod performance status of 0, 1, or 2
boolean
C3714786 (UMLS CUI [1])
Hematologic function | Absolute neutrophil count | Segmented neutrophil count | Neutrophil Band Cells | Total white blood count | Platelet Count measurement
Item
7. acceptable hematologic status within two weeks prior to patient registration, including: (a) absolute neutrophil count ([segmented neutrophils + bands] * total white blood count (wbc)) >/= 1,500/mm^3; (b) platelet counts >/= 100,000/mm^3.
boolean
C0221130 (UMLS CUI [1])
C0948762 (UMLS CUI [2])
C1168341 (UMLS CUI [3])
C3661517 (UMLS CUI [4])
C1271681 (UMLS CUI [5])
C0032181 (UMLS CUI [6])
Gender Pregnancy Absent | Gender Breast Feeding Absent
Item
8. female patients who are not pregnant or lactating
boolean
C0079399 (UMLS CUI [1,1])
C0032961 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0079399 (UMLS CUI [2,1])
C0006147 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
Reproductive potential Contraceptive methods
Item
9. men and women of reproductive potential who are following accepted birth control methods (as determined by the treating physician)
boolean
C4034483 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
Pharmaceutical Preparations Previous | Toxicity Long-term Unexpected | Pharmaceutical Preparations Discontinued | Toxicity post treatment Absent
Item
10. patients previously on phase ii drugs if no long-term toxicity is expected, and the patient has been off the drug for eight or more weeks with no significant post treatment toxicities observed
boolean
C0013227 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0600688 (UMLS CUI [2,1])
C0443252 (UMLS CUI [2,2])
C4055646 (UMLS CUI [2,3])
C0013227 (UMLS CUI [3,1])
C1444662 (UMLS CUI [3,2])
C0600688 (UMLS CUI [4,1])
C2709088 (UMLS CUI [4,2])
C0332197 (UMLS CUI [4,3])
Lymphoma Bone Marrow Involvement Percentage | Bone marrow aspirate examination | Bone marrow biopsy
Item
11. patients determined to have < 25% bone marrow involvement with lymphoma within six weeks of registration (define measurement of a bone marrow aspirate or biopsy) (this criteria must be strictly met for adequate patient safety.)
boolean
C0024299 (UMLS CUI [1,1])
C1517677 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
C1271729 (UMLS CUI [2])
C0005954 (UMLS CUI [3])
Lesion size Linear Quantity
Item
12. patient should have at least one lesion measuring >/= 2 cm in a single dimension.
boolean
C0449453 (UMLS CUI [1,1])
C0205132 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
Myeloablative Chemotherapy | Autologous bone marrow transplant | Peripheral Stem Cell Transplantation
Item
1. prior myeloablative therapies with autologous bone marrow transplantation (abmt) or peripheral blood stem cell (pbsc) rescue.
boolean
C1513784 (UMLS CUI [1])
C0194037 (UMLS CUI [2])
C0242602 (UMLS CUI [3])
Platelet Count measurement
Item
2. platelet count< 100,000 cells/mm^3.
boolean
C0032181 (UMLS CUI [1])
Bone marrow depression
Item
3. presence of hypocellular bone marrow.
boolean
C0151773 (UMLS CUI [1])
Stem cell collection failed
Item
4. patients with history of failed stem cell collection.
boolean
C3827940 (UMLS CUI [1,1])
C0231175 (UMLS CUI [1,2])
Radioimmunotherapy
Item
5. prior radioimmunotherapy
boolean
C0085101 (UMLS CUI [1])
Central nervous system lymphoma
Item
6. presence of central nervous system (cns) lymphoma
boolean
C0742472 (UMLS CUI [1])
HIV Infection
Item
7. patients with hiv.
boolean
C0019693 (UMLS CUI [1])
Pleural effusion
Item
8. patients with pleural effusion
boolean
C0032227 (UMLS CUI [1])
Liver Dysfunction | Serum total bilirubin measurement
Item
9. patients with abnormal liver function: total bilirubin > 2.0 mg/dl
boolean
C0086565 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
Abnormal renal function | Creatinine measurement, serum
Item
10. patients with abnormal renal function: serum creatinine > 2.0 mg/dl
boolean
C0151746 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
Teleradiotherapy procedure Bone Marrow Percentage
Item
11. patients who have received prior external beam radiation therapy to > 25% of active bone marrow (involved field or regional)
boolean
C0419095 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
Growth Factor Support Effective short-term | Leukine | Neupogen | Procrit | Growth Factor Support Effective long-term | Aranesp | Neulasta
Item
12. patients who have received short-acting growth factor support (leukine, neupogen, procrit) within 2 weeks prior to treatment or long-acting growth-factor support (aranesp), neulasta) within 4 weeks prior to treatment.
boolean
C0018284 (UMLS CUI [1,1])
C0344211 (UMLS CUI [1,2])
C1280519 (UMLS CUI [1,3])
C0443303 (UMLS CUI [1,4])
C0701500 (UMLS CUI [2])
C0733468 (UMLS CUI [3])
C0733467 (UMLS CUI [4])
C0018284 (UMLS CUI [5,1])
C0344211 (UMLS CUI [5,2])
C1280519 (UMLS CUI [5,3])
C0443252 (UMLS CUI [5,4])
C1134440 (UMLS CUI [6])
C1171279 (UMLS CUI [7])
Disease Serious compromises Protocol Compliance | Communicable Disease Serious compromises Protocol Compliance
Item
13. serious nonmalignant disease or infection which, in the opinion of the investigator and/or the sponsor, would compromise other protocol objectives
boolean
C0012634 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C2945640 (UMLS CUI [1,3])
C0525058 (UMLS CUI [1,4])
C0009450 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C2945640 (UMLS CUI [2,3])
C0525058 (UMLS CUI [2,4])
major surgery | Diagnostic surgical procedure
Item
14. major surgery, other than diagnostic surgery, within four weeks
boolean
C0679637 (UMLS CUI [1])
C0522769 (UMLS CUI [2])
Cell transformation Evidence Biopsy
Item
15. evidence of transformation in the latest biopsy
boolean
C0040682 (UMLS CUI [1,1])
C3887511 (UMLS CUI [1,2])
C0005558 (UMLS CUI [1,3])